

# Reshaping the tumor stroma: emerging therapies in pancreatic cancer

## Short title: Stromal therapies for pancreatic cancer

Claire Vennin<sup>1</sup>, Kendelle J. Murphy<sup>1</sup>, Jennifer P. Morton<sup>2</sup>, Thomas R. Cox<sup>1</sup>, Marina Pajic<sup>1,\*</sup> & Paul Timpson<sup>1,2</sup>

1. The Garvan Institute of Medical Research, Sydney Australia; The Kinghorn Cancer Center, Sydney Australia, St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney Australia

2. Cancer Research UK, The Beatson Institute for Cancer Research, Glasgow, Scotland UK.

\* Authors for correspondence: **Dr. Marina Pajic**: [m.pajic@garvan.org.au](mailto:m.pajic@garvan.org.au), the Garvan Institute of Medical Research, 384 Victoria Street 2010 Darlinghurst NSW Australia, and **Associate Professor Paul Timpson**, [p.timpson@garvan.org.au](mailto:p.timpson@garvan.org.au), the Garvan Institute of Medical Research, 384 Victoria Street 2010 Darlinghurst NSW Australia.

## Funding

The work was supported by NHMRC, NBCF, Cancer Institute NSW, an Australian Research Council, Future Fellowship, a Len Ainsworth Pancreatic Cancer Fellowship, a Philip Hemstritch Fellowship in Pancreatic Cancer, Avner Pancreatic Cancer Foundation, a Sydney Catalyst scholarship, Cancer Council NSW, Tour de Cure and a CRUK core grant.

Authors' contribution: C.V., K.J.M., J.P.M., T.R.C., M.P. and P.T. wrote the manuscript; C.V. and K.J.M. designed the figures.

## **Abstract**

Pancreatic cancer is accompanied with a fibrotic reaction that alters interactions between tumor cells and the stroma to promote tumor progression. Consequently, strategies to target the tumor stroma might be used to treat patients with pancreatic cancer. We review recently developed approaches for re-shaping the pancreatic tumor stroma and discuss how these might improve patient outcomes. We also describe relationships between the pancreatic tumor extracellular matrix, the vasculature, the immune system, and metabolism and discuss the implications for the development of stromal compartment-specific therapies.

Keywords: pancreatic cancer, stromal remodeling, invasion, metastasis, diagnostic tool, patient-derived models

39	<b>List of abbreviations:</b>
40	AMP: Adenosine Monophosphate-Activated Protein
41	ACTA: Alpha-Smooth Muscle Actin
42	ATRA: All-Trans Retinoic Acid
43	CAF: Cancer-Associated Fibroblasts
44	CTC: Circulating Tumor Cell
45	ECM: Extracellular Matrix
46	EMT: Epithelial to Mesenchymal Transition
47	FAP: Fibroblast Activated Protein
48	HA: Hyaluronic Acid
49	LOX: Lysyl Oxidase
50	MMP: Matrix Metallo-Proteinase
51	PET: Positron Emission Tomography
52	PDX: Patient Derived Xenograft
53	PSC: Pancreatic Stellate Cell
54	TAM: Tumor Associated Macrophage
55	VEGF: Vascular Endothelial Growth Factor
56	

Pancreatic cancer is predicted to be the second-largest cause of cancer-related death by 2030 and fewer than 7% of patients survive for 5 years<sup>1</sup>. We therefore need to identify new therapeutic targets and radically rethink our approach to developing treatments for patients with pancreatic cancer. Pancreatic cancer progression is accompanied with a fibrotic stromal (desmoplastic) reaction, characterized by extensive deposition of extracellular matrix (ECM) components, recruitment and activation of cancer-associated fibroblasts (CAFs), decreased vasculature patency and altered immune-surveillance<sup>2,3</sup>. Stromal remodeling leads to altered interactions between tumor cells and stromal compartments, which can promote tumor progression<sup>4</sup>. Studies have shown that the stroma can promote and prevent pancreatic cancer progression, highlighting that multiple considerations should be taken into account when clinically translating stromal-based therapies<sup>5</sup>.

We review the importance of the different stromal compartments, strategies for targeting them or re-shaping the pancreatic tumor stroma, and we explore their potential to improve outcomes of patients with pancreatic cancer. In particular, we outline how short-term, fine-tuned manipulation of interactions between cancer cells and the stroma, both in primary and metastatic sites (such as the liver), can improve the efficacy of chemotherapy and reduce growth of metastases while maintaining normal tissue functions. We discuss findings from studies reporting the intricate interactions between different elements of the stroma (such as the ECM, CAFs, immune cells, blood, and the lymphatic vasculature) and how these affect the development of new stromal-based treatments for pancreatic cancer. We also summarize recently developed diagnostic tools and pre-clinical models that can be used to assess individualized stromal-based therapies. Lastly, we discuss how discoveries from research on other types of tumors with high levels of fibrosis could be repurposed in pancreatic cancer.

## **Fine-Tuned Manipulation of the Interactions Between Tumor Cells and ECM**

Within pancreatic tumors, extensive remodeling of the ECM can increase tissue stiffness to mechanically induce intracellular signaling that promotes disease progression<sup>6</sup>. Remodeling of the ECM does not occur evenly throughout the tumor—it was recently shown to be heterogeneous and spatially well-defined within pancreatic tumor tissues and to correlate with clinical and pathology features of patient tumors<sup>7</sup>. Although ECM remodeling has been proposed to be predominantly mediated by activated stromal cells such as CAFs<sup>8</sup>, cancer cell

tension, mediated for instance by JAK signaling via STAT and ROCK, can tune the pancreatic ECM and thereby mechanically activate signaling pathways that regulate survival and metastasis in pancreatic cancer cells<sup>7,9</sup>. Similarly, increased stiffening of the ECM has been reported to promote the epithelial-to-mesenchymal transition (EMT) in pancreatic tumor cells, a key step of the metastatic cascade, and to reduce their response to chemotherapy<sup>7,10-12</sup>.

#### *Targeting mechanical features of the ECM*

The mechanical features of the ECM can determine pancreatic cancer aggressiveness. Consequently, disruption of the mechanical feedback between tumor cells and the ECM, or mechano-reciprocity<sup>6</sup>, has been evaluated as an approach to impair pancreatic cancer progression. Initial studies assessing ECM targeting have demonstrated that reducing fibrosis in pancreatic tumors is possible by inhibiting the fibrotic Hedgehog (Hh) signaling pathway<sup>13</sup> or by targeting hyaluronic acid (HA) with PEGPH20 (PEGylated hyaluronidase)<sup>14,15</sup> in *Pdx1-cre; Kras<sup>G12D</sup>; p53<sup>fl</sup>* (KPC) mice bearing primary tumors<sup>16,17</sup>. These strategies led to reduced intra-tumor pressure, increased vasculature patency, and longer survival times of KPC mice.

The efficacy of anti-ECM agents in combination with chemotherapy has also been assessed in clinical trials of patients with pancreatic cancer. For instance, vismodegib, IPI-926 (hedgehog inhibitors, NSC74769<sup>18</sup> and NCT01383538<sup>19</sup>) or PEGPH20 (NCT01839487<sup>20</sup>, Table 1) have been tested in combination with chemotherapy. In addition, PEGPH20 is also currently being tested in patients where high HA deposition in their tumors is assessed as a marker for response to treatment (HaLo 109-202, Table 1). The promising interim results from these trials led to a Phase 3 trial for PEGPH20 in combination with gemcitabine and abraxane (NCT02715804, HaLo 301). Moreover, a phase 1b/2 study of PEGPH20 in combination with anti-PDL1 cancer immunotherapy is also underway<sup>21</sup> (Table 1).

Inhibition of lysyl oxidase (LOX), an enzyme required for collagen biogenesis and crosslinking, which is overexpressed in hypoxic tumor environments, was also assessed in KPC mice. In KPC mice with pancreatic primary tumors, the combination of a LOX blocking antibody with gemcitabine reduced ECM crosslinking, blocked metastasis, and increased survival times, compared to gemcitabine alone<sup>22</sup>. The increased efficacy of gemcitabine upon LOX inhibition was not due to increased vasculature patency or drug delivery, suggesting that manipulation of the ECM and of mechano-reciprocity using LOX inhibitors might

deprive cancer cells of mechanical survival cues that promote metastasis and resistance to treatment<sup>22</sup>. Interestingly, inhibition of LOX in combination with gemcitabine in mice with locally advanced tumors, with a well-established matrix, did not significantly increase survival<sup>22</sup>. As LOX inhibition blocks only progressive cross-linking of the ECM and does not reverse previous LOX-induced changes to the ECM, these findings indicate that agents to manipulate the ECM are likely to have tumor stage-dependent effects. In light of this, ECM biomarkers could be used to identify tumors most likely to respond to these agents.

Studies of stroma-targeting agents in mouse models of pancreatic tumors have mainly been tested in mice with early-stage (primary) tumors, and have provided insights into the effects of long-term stromal manipulation<sup>14, 15, 23-25</sup>. However, most patients present with late-stage pancreatic cancer and metastases. Consequently, there are valid arguments for testing anti-stroma agents in mice with early- or late-stage tumors to optimize stromal agents in combination with standard-of-care therapies in both settings<sup>26, 27</sup> (Fig. 1A). In addition, studies using human pancreatic tumor tissues and mathematical modeling have shown that these tumors do not always progress in a linear or gradual manner, but rather can be a result of fast and simultaneous accumulation of genetic alterations that lead to early dissemination of tumor cells<sup>28</sup>. This finding suggests that testing anti-stroma agents in mice with localized primary tumors and with metastatic tumors, rather than optimizing the timing of anti-stroma agent administration, could be beneficial.

Tissue stiffening is also mediated by cell contractility, which is in part regulated by Rho kinase (ROCK) signaling<sup>29-31</sup>. Expression of ROCK1 and ROCK2 were recently found to be increased in human pancreatic tumors with stage and grade, and genomic alterations in *ROCK1* and *ROCK2* correlated with shorter survival times of patients<sup>32</sup>. Interestingly, ROCK2 activation in non-invasive pancreatic cancer cells promoted their invasion of a collagen matrix and increased ECM remodeling, potentially via an increased release of matrix metalloproteinases (MMPs) into the surrounding environment<sup>32</sup>. In line with this, short-term inhibition of ROCK activity, via oral administration of fasudil as a priming agent before administration of a chemotherapeutic reduced fibrosis in pancreatic tumors<sup>33</sup>. Intravital imaging analyses of single cells in primary and metastatic pancreatic tumors showed that pulsed and iterative priming with fasudil, rather than chronic exposure to anti-ECM drugs (Fig. 1B), reduced ECM crosslinking, increased vasculature patency and enhanced the effects of chemotherapeutic agents<sup>33</sup>. Survival and proliferative stimuli provided by the ECM are

partly mediated by integrins and Src signaling, and these were also reduced in tumors primed with fasudil. Src can promote progression of pancreatic tumors by reducing their responses to chemotherapy<sup>34</sup> and increasing their invasive activities<sup>35</sup>. Because fasudil priming reduces Src activity, anti-stromal priming agents such as these could potentially be employed as an anti-invasive approach in pancreatic cancer. This is in line with recent assessment of Src inhibition post-surgery in pancreatic cancer<sup>36, 37</sup>. Fine-tuned ROCK inhibition also reduced cancer cell resistance to shear stress in the blood circulation, decreased cancer cell seeding in the liver, and inhibited the establishment of a fibrotic environment that supports growth of metastases<sup>33</sup>, as recently reported in models of melanoma<sup>38</sup>.

Together, these findings indicate that short-term, sequential and pulsed administration of anti-fibrotic agents allows subtle manipulation of the ECM and deprives cancer cells of a supportive mechanical niche<sup>3, 6, 31, 33</sup>. This is an important advantage of fine-tuned ECM targeting, since chronic, systematic ablation of fibrosis can be accompanied with enhanced metastasis and increased tumor infiltration by immune cells that support tumor progression<sup>23, 24</sup> (Figs. 1B and 2A).

#### *Inhibiting the ability of the ECM to promote metastasis*

Although remodeling of the ECM accompanies primary tumor progression, alterations of the tumor ECM can also mediate metastasis<sup>39</sup>. Changes of the ECM in distant organs before seeding of metastatic cells can be mediated by exosomes released by primary tumor cells. For instance, pancreatic cancer cell-derived exosomes can accumulate in other tissues, such as the liver, to create a pre-metastatic niche by activating hepatic stellate cells and Kupffer cells<sup>39, 41</sup>. This was shown to induce remodeling of the host ECM and to facilitate cancer cell invasion and growth in the liver.

Surgical resection of primary tumors has also been reported to alter the ECM in other tissues such as the lungs<sup>42</sup>, and to thereby increase the ability of circulating tumor cells to form metastases at these sites compared to mice that were not undergoing surgery<sup>42</sup>. Given that approximately 20% of patients with pancreatic cancer are eligible for surgical resection of primary tumors, this may have implications in this disease too. In addition, local changes to the ECM in secondary organs can reawaken disseminated and dormant tumor cells (identified as single, non proliferative tumor cells), which could then form metastases. Activation of dormant tumor cells by a fibrotic matrix can be prevented by blocking

mechanical interactions between tumor cells and the ECM<sup>43</sup>. Conversely, cell quiescence and dormancy can be induced by ECM components such as lumican—further highlighting how the ECM can promote and impair tumor progression at multiple stages<sup>44</sup>. FOXO4 was recently identified as a regulator of cell senescence and dormancy, and inhibiting interactions between FOXO4 and p53 with a FOXO4 peptide caused apoptosis specifically in senescent and dormant cells<sup>45</sup>. Combinations of such pharmacological agents that induce death of dormant cells and anti-stroma agents could be repurposed to prevent cancer recurrence caused by dormant pancreatic cancer cells<sup>46, 47</sup>.

Collectively, these studies show how primary tumor can induce early stromal alterations in other tissues to promote cancer spread. This highlights the need for assessing anti-stromal agents in combination with chemotherapy in the neo-adjuvant and adjuvant settings to reduce the risk of tumor dissemination<sup>22, 39-41, 48-50</sup> (Fig. 1A). In addition, in patients with late-stage pancreatic cancer, tissues containing metastases or pre-metastatic lesions have already recruited CAFs, increased the density of collagen I fibers and HA, become hypovascular, and induced changes in the anti-tumor immune response<sup>51</sup>. Consequently, strategies aimed at reversing stromal alterations in secondary sites to restore normal tissue homeostasis and mechanical properties might also impair pancreatic cancer progression (Fig. 1A).

### **Stromal Targets for Fine-Tuning the ECM in Pancreatic Cancer**

Additional regulators of ECM stiffening and mechano-signaling, such as FAK, MMPs, SerpinB2, RhoA, JAK/STAT, YAP/TAZ, CDK4 and PAK, which are known to play vital roles in mechano-reciprocity and cancer development, might also be targeted to prevent pancreatic tumor progression<sup>7, 32, 52-57</sup> (Fig. 2A). For example, the activity of RhoA was recently demonstrated to switch during pancreatic cancer development and metastasis<sup>58</sup>. Given the role of RhoA in regulating the interactions between tumor cells and the surrounding stroma, this calls for careful consideration for the development of fine-tuned targeting of RhoGTPases in pancreatic cancer<sup>58, 60</sup>. In addition, in pancreatic cancer cells that have lost p53 function (*TP53* is frequently mutated in pancreatic cancer cells)<sup>61</sup>, JAK2 signaling via STAT3 has been shown to promote activation of pancreatic stellate cells (PSCs) and to increase ECM remodeling<sup>62</sup>. Similarly, mechanically induced FAK activity can help establish a fibrotic and immunosuppressive environment, and FAK inhibition in combination with immunotherapy



was shown to double survival times of mice with pancreatic tumors<sup>54</sup>. These observations led to studies of the efficacy of the FAK inhibitor defactinib in combination with anti-PD1 antibody and gemcitabine in patients with advanced pancreatic cancer (phase 1, NCT02546531; study still recruiting, see Table 1).

Importantly, these signaling pathways are not active in only pancreatic cancer cells. Indeed, changes in tumor–stroma interactions have been reported to affect the mechanical features of liver tumors<sup>55</sup>, melanomas<sup>52</sup>, breast tumors<sup>49, 63</sup>, and glioblastoma<sup>64</sup>. Consequently agents designed to alter mechanical feedback from the ECM could also be beneficial in these contexts.

### **Simultaneous manipulation of distinct stromal compartments in pancreatic cancer**

Although manipulation of the mechanical features of the ECM disrupts intracellular signaling and thereby promotes pancreatic tumor progression, alterations of the ECM can also induce changes in the intra-tumor vasculature. For instance, increases in matrix stiffness were shown to induce invasion of endothelial cells and formation of new vessels, potentially via upregulation of MMPs in endothelial cells. These changes also reduced vessel barrier function, as demonstrated in experiments in which Evans Blue was injected into mice, and could be reversed by blocking collagen crosslinking<sup>65</sup>. Similarly, increased tissue stiffness has been shown to induce cadherin 2 (CDHN) presentation on the surface of endothelial cells, thereby facilitating cancer cell interactions with the endothelium and metastasis<sup>66</sup>.

Conversely, changes in tissue vascularity can modulate the properties of the ECM. For example, proteomic analyses of the ECM in decellularized pancreatic tissues undergoing angiogenesis revealed that numerous ECM proteins are differentially regulated during angiogenesis. These include fibrillin 1, Von Willebrand factor A domain containing 5a, and hemicentin; none of these had previously been associated with pancreatic cancer progression<sup>67</sup>.

Due to the intricate interactions between the tumor ECM and vasculature, manipulation of one compartment might affect another stromal component. This was recently assessed in a mouse model of metastatic colorectal cancer, in which administration of blocking antibodies against VEGF to impair angiogenesis was associated with increased ECM remodeling and enhanced deposition of HA in liver metastases<sup>68</sup>. Enzymatic depletion of HA following anti-

VEGF administration increased tissue perfusion and thereby prolonged survival of mice, compared to mice that received only anti-VEGF agents<sup>68</sup>, demonstrating the increased benefit of sequential targeting of both compartments (Fig. 1B and 2B). In line with this, manipulation of the ECM in fibrosarcoma increased the permeability of the tumor vasculature and response to anti-VEGF agents<sup>69</sup>. In addition, Frentzas et al reported interactions between the ECM and vasculature in liver metastases in human and in mice. Here, the authors demonstrated that metastatic emboli surrounded by a fibrotic capsule respond well to anti-angiogenic agents, whereas metastases progressing without a fibrotic tissue were resistant to these drugs<sup>70</sup>. These findings indicate the potential benefits of dual, or sequential, targeting of the ECM and vasculature and such approaches might be used in the treatment of pancreatic cancer (Fig. 1B). These studies also suggest that combinations of markers of the tumor ECM and vasculature might be used to identify patients most likely to benefit from dual manipulation of the ECM and vasculature.

### **Manipulating Pancreatic Tumor Immune Response**

While pancreatic cancer cells often display oncogenic mutations that affect anti-tumor immunity, the fibrotic reaction also affects the immune response in pancreatic tumors<sup>61, 71, 72</sup>. For instance, low infiltration of tumors by T cells has been correlated with poor outcomes<sup>73</sup>, and PSCs and CAFs have been reported to reduce T-cell infiltration of the tumor site<sup>74</sup>. Treating KPC mice with all-trans retinoic acid (ATRA) to render PSCs and CAFs more quiescent increased T-cell infiltration into pancreatic tumors, and prolonged survival<sup>74, 75</sup>. Furthermore, CAFs can secrete CXCL12, which binds to cancer cells and protects them from T-cell induced apoptosis<sup>76</sup>. Depletion of CAFs that express fibroblast-activation protein (FAP) increased T-cell infiltration of tumors and enhanced the efficacy of anti-PD-L1<sup>76, 77</sup>. This suggests that manipulating, rather than eliminating CAFs (for which increased infiltration of tumors with immune cell that promote cancer progression has been reported) might increase the efficacy of immune-based therapies for pancreatic cancer (Fig. 2C). Such strategies could be achieved using pharmacologic agents, such as osteopontin-neutralizing antibodies or vitamin D, which have both been shown to deactivate CAFs<sup>78, 79</sup> (Table 1). In addition, ATRA is being tested in combination with gemcitabine and abraxane in a phase 1 clinical trial in pancreatic cancer (the STARPAC study); and given the interactions between CAFs and T

cells within tumors, ATRA could also be tested in combination with immunotherapy (Fig. 2C and D, Table 1).

Immune cells recruited to tumor tissues can also affect some features of the tumor ECM. Tumor-associated macrophages (TAMs) have been reported to promote deposition and crosslinking of ECM components such as collagens and fibronectin<sup>80</sup>. Immune cells might therefore also be involved in shaping the tumor ECM, and thus could be targeted to not only improve the anti-tumor immune response but also to reduce ECM stiffness in pancreatic tumors (Fig. 2D).

Although the work described above report that CAFs potentially reduce T-cell infiltration of tumors<sup>74,75</sup>, studies that mapped T cells within mouse and human pancreatic cancer tissues using multiplex immune-labelling and computational imaging did not correlate T-cell infiltration with the abundance of collagen I or alpha-smooth muscle actin (ACTA)-positive CAFs<sup>91</sup>. This implies that the relationships between T cells, CAFs, and fibrosis might be more complicated and heterogeneous than previously reported. A potential explanation of these results may be that rather than homogenous fibroblastic population, heterogeneous subtypes of CAFs co-exist in tumor tissues, and have distinct roles in promoting ECM remodeling, recruitment of immune cells, and response to therapy<sup>82,84</sup> (Fig. 2C). Researchers have described 2 populations of CAFs which are spatially separated in pancreatic tumor tissues: ACTA<sup>High</sup> CAFs and ACTA<sup>Low</sup>/IL6<sup>High</sup> CAFs<sup>84</sup>. ACTA<sup>High</sup> CAFs were shown to promote ECM remodeling, whereas ACTA<sup>Low</sup>/IL6<sup>High</sup> CAFs secreted higher levels of cytokines<sup>84</sup>. Moreover, CDHN-expressing CAFs have been shown to promote cancer cell collective invasion. Here, heterotypic interactions between CDHN on CAFs and cadherin 1 on cancer cells allowed the transmission of mechanical forces and induced collective cell movement<sup>85</sup> (Fig. 2C). Similarly, CAFs have been shown to have a heterogeneous epigenetic signature and varying patterns of gene expression, and these are associated with ECM remodeling, angiogenesis, inflammation, and metastasis<sup>86,87</sup>. In addition, although cancer cells can induce epigenetic changes in CAFs, targeted therapies might also affect their epigenetic regulation. Consequently, assigning CAFs to subgroups based on their histologic, epigenetic, mechanical and/or immunologic profiles could be used to target specific sub-populations while leaving other fibroblast populations intact (Fig. 2C, D). Together, these studies suggest that subtle, context-dependent targeting of specific CAF populations, rather than complete ablation of

CAFs, could be beneficial in pancreatic cancer (Fig. 2C, D). This aligns with observations discussed above for subtle manipulation of ECM stiffness.

During tumor progression, the vasculature also interacts with the immune system, and this has implications for the development of anti-stroma agents. For example, chronic stress was shown to induce dissemination of pancreatic cancer cells via the lymphatic vasculature network, and this was supported by TAMs. Interestingly, blocking the recruitment of macrophages to the tumor site reduced lymphatic network remodeling and the subsequent dissemination of cancer cells<sup>88</sup> (Fig. 2D). In addition, targeting beta-adrenergic stress-responsive signaling using beta-blockers reverted stress-induced lymphatic changes and reduced metastasis (Fig. 2B). Beta-blockers are already used in the clinic to control blood pressure, so their effects on pancreatic tumor metastases should be evaluated. Beta-blockers are being tested in a phase 2 trial of patients with breast cancer (ACTRN12615000889550, Table 1). In addition, in a phase 2 trial of patients with pancreatic cancer, beta-blockers will be combined with non-steroidal anti-inflammatory drugs, as a perioperative therapy (personal communication, M. Diener, E. Sloan, and I. Rooman).

Analyses of gene expression patterns in human breast cancer tissues demonstrated a positive correlation between expression of genes that regulate vessel normalization with immune-stimulatory signaling pathways<sup>89</sup>. In mice bearing tumors, disruption of vessel normalization reduced T-cell infiltration, while blockade of T-cell activity reduced tumor vessel pericyte coverage. In addition, immune checkpoint blockade increased vessel patency and reduced hypoxia in patient-derived xenografts (PDXs)<sup>90</sup>. Similarly, normalization of the vasculature using A2V, an inhibitor of angiopoietin 2 and VEGFA, led to recruitment of TAMs, dendritic cells, and T cells to different types of tumors, including neuroendocrine pancreatic tumors<sup>90,91</sup>. The studies also revealed that administration of A2V combined with PD1 blockade significantly increased T-cell activation and prolonged survival of mice<sup>90,91</sup> (Fig. 2B and D). Together, findings from these studies indicate that manipulation of the tumor vasculature and tumor immune response might be more beneficial than targeting a single stromal compartment (Fig. 1B); these findings could be applied to pancreatic cancer, in which both the tumor vasculature and immunity are compromised.

The development of immune-based therapies for pancreatic cancer has proven to be challenging, because of the tumor's poor antigenicity, dense fibrotic stroma and

immunosuppressive environment, leading to a paucity of infiltrating T cells<sup>91</sup>. Recently, immune-based targets have been identified and have shown promising results in mice. In patients with pancreatic cancer, expression of the neutrophil-homing receptor CXCR2 and its ligands<sup>92,93</sup> correlated with lower survival times<sup>48</sup>. Inhibition of CXCR2 using a small molecule inhibitor in KPC mice reduced ECM remodeling and increased infiltration of neutrophils, macrophages, and T cells into the tumor, while also reducing metastases. In addition, sequential blocking of CXCR2 to increase T-cell infiltration followed by administration of anti-PD1 significantly prolonged survival in mice with established tumors. This may be a promising treatment for pancreatic cancer and is being assessed in a phase 1 clinical trial (NCT02583477, Fig. 2A, D, Table 1). Similarly, TAMs can also affect response to treatment<sup>94</sup>, and manipulating their effects has been suggested to increase the efficacy of immune checkpoint inhibitors. Indeed, TAMs can capture anti-PD1 antibody, potentially via Fcγ receptor, and prevent activation of T cells. Blockade of Fcγ receptor before administration of anti-PD1 antibody significantly increased the efficacy of immunotherapy, and such approach could be used for the development of immune-based therapies in pancreatic cancer<sup>95</sup> (Fig. 2D). The efficacy of anti-PD1 agents can be increased by administration of anti-OX40 agents. For instance, sequential administration of anti-OX40 to increase T-cell activation, followed by administration of anti-PD1 agents, delayed tumor growth and increased survival compared to anti-PD1 alone<sup>96</sup>. Importantly, concurrent administration of anti-OX40 and anti-PD1 agents, rather than sequential administration, did not increase survival times of mice but instead provoked a cytokine storm-like event. In addition, sequential administration of anti-PD1 agent first followed by OX40 blockade failed to increase survival, demonstrating that timing and order are crucial for the combination of anti-OX40 plus anti-PD-1 agents<sup>96,97</sup> (Fig. 2D).

These findings might guide clinical studies of the efficacy of anti-OX40 antibodies such as MOXR0916 and GSK3174998, in combination with anti-PD1/PDL1 agents for patients with solid tumors<sup>98</sup> (NCT02410512; NCT02528357, Table 1). Given the subtle balance of the tumor immune landscape in pancreatic cancer, sequential administration of immune-based agents, rather than concurrent administration should be considered for the development of immunotherapies<sup>79</sup> (Fig. 1B).

## Effects of the Stroma on Cancer Cell Metabolism

Alterations in the stroma during pancreatic tumor progression have also been shown to affect cancer cell metabolism<sup>99</sup>. Given the metabolic switch occurring in cancer cells during tumor progression, this may have implications for the development of anti-stroma agents. Signaling from activated PSCs can induce metabolic changes in cancer cells, such as secretion of non-essential amino-acids, which fuel the tricarboxylic acid cycle and mitochondria metabolism in cancer cells<sup>100, 101</sup>. Similarly, patient-derived CAFs were shown to release exosomes, which can be taken in by cancer cells and inhibit mitochondrial oxidative phosphorylation, increase glycolysis and glutamine-dependent reduction of carbon in cancer cells<sup>102</sup>. On the other hand, cancer cell metabolic pathways may also shape some features of the ECM. As such, AMP-kinase, a metabolic sensor, was recently shown to regulate the activity of  $\beta$ 1-integrin and to affect fibronectin remodeling induced by fibroblasts<sup>103, 104</sup>. Here, fibroblasts derived from AMPK knock-out mice assembled more fibronectin and had higher mechano-reciprocity, indicating a connection between metabolic activity and cell stiffness<sup>103, 104</sup>. Moreover, pancreatic tumor cells can scavenge and degrade extracellular proteins through macropinocytosis and thereby acquire nutrients that support their metabolic activity<sup>105</sup>. For instance, using a micro-device to deliver labeled extracellular proteins into pancreatic tumors, Davidson et al monitored albumin and fibronectin uptake and catabolic degradation specifically by cancer cells and not by adjacent non-cancerous pancreatic tissue<sup>106</sup>. In addition, blocking macropinocytosis in pancreatic tumors of mice via administration of 5-(N-Ethyl-N-isopropyl)-amiloride led to reduced levels of amino acids in pancreatic cancer cells. This could be an interesting approach to deprive cancer cells of metabolic factors provided by the extracellular compartment (Fig. 2E).

Obesity, a factor for pancreatic cancer<sup>107</sup>, has been shown to trigger inflammation and fibrosis within pancreatic tumor tissues. As such, growth of pancreatic primary tumors, orthotopic xenograft tumors, and metastases were all accelerated in obese mice compared with lean mice<sup>108</sup>. Obesity was also reported to promote remodeling of the tumor ECM and vasculature and to reduce drug diffusion into tumor tissue. In addition, tumor infiltration by Ly6G<sup>+</sup> lymphocytes was increased in obese mice compared to lean mice and inhibiting these lymphocytes reduced activation of PSCs, decreased fibrosis, and increased vasculature patency<sup>108</sup>. This study demonstrates complex, subtle crosstalk between obesity, ECM remodeling, the vascular network, and the immune response within pancreatic tumors. It also

suggests that stromal intervention could be fine-tuned based on the metabolic profile of patients or pancreatic tumors.

Lastly, metabolic agents such as metformin (used to treat metabolic diseases)<sup>109</sup>, lactate dehydrogenase<sup>110</sup>, or glutaminase inhibitors<sup>111</sup> were recently suggested to be beneficial for patients with pancreatic cancer and could be combined with other anti-stromal drugs to slow development of pancreatic cancer (Fig. 2E). Serine and glycine were also recently shown to promote cancer progression in genetically engineered mouse models of intestinal cancer and lymphoma<sup>112</sup>. Restriction of serine and glycine prolonged survival of *Apc*<sup>Min/+</sup> mice, which develop intestinal adenomas. However, the anti-tumor effects of serine and glycine starvation were moderate in KPC mice, so although dietary changes appear to potentially impair cancer progression in some cases, specific genetic features of patients and their tumors may need to be factored in to predict response to serine and glycine starvation in combination with stromal therapies (Fig. 2E).

This body of work suggests that concomitant manipulation of multiple stromal compartments before administration of standard-of-care therapies can be more beneficial than single targeting alone (Fig. 1B). However, the timing of administration of stroma-targeting agents must be carefully optimized and balanced to maximize the effects of anti-cancer drugs. Recently, more than 10,000 sequential drug combinations were screened using systematic cell imaging and global Bayesian analysis and this was employed for melanoma and pancreatic cancer cell lines<sup>113</sup>. The authors identified multiple time-dependent, sequential drug combinations which may be relevant for the treatment of pancreatic cancer cells<sup>113</sup>. Screening platforms such as these could be combined with 3-dimensional tumor stroma models described below to optimize sequential administration of anti-stroma agents. In addition, chemotherapies not only kill cancer cells but can also have unintended negative effects on stromal compartments<sup>114-116</sup>. Therefore, the addition of the anti-stromal effects of chemotherapy with those of anti-ECM agents needs to be fine-balanced in order to maximize anti-tumor effects and minimize negative effects.

## **Technologies for Detection of Pancreatic Cancer**

Although strategies to target the tumor stroma have the potential to improve outcomes of pancreatic cancer, the lack of sensitive diagnostic tools poses a critical challenge to early treatment. However, recently developed technologies such as liquid biopsies and live

imaging techniques could facilitate identification of early-stage tumors in patients (Fig. 3). Markers in the circulation, such as CTCs, circulating tumor DNA, carcinoembryonic antigen, and cancer antigen 19-9 (CA 19-9), have been used to detect pancreatic tumors in humans and in mice, in a non-invasive and cost-effective manner. However, tests for these markers sometimes lack sensitivity and yield high false-positive rates<sup>117,118</sup>.

Recently, circulating extracellular vesicles (cEVs) in the blood of patients with cancer or of mice bearing tumors have been reported to successfully determine prognosis (Fig. 3A). Specifically, molecules carried by cEVs, such as microRNA23b3p3, microRNA10b, microRNA30c, mutant Kras, CD44v5, Tspan8, MET, and CD104 have been suggested to facilitate detection of pancreatic cancer<sup>119,122</sup>.

Isolation of tumor-derived cEVs requires large volumes of blood and can be technically challenging, time-consuming, and costly. Platforms are being developed for faster and more accurate detection of cEVs from patients' blood. One such example is a plasmonic-sensing system that has been developed for high-throughput and cost-effective detection of cEVs<sup>123</sup> (Fig. 3A). This platform identified a cEV-based signature composed of 5 markers that correlate with presence of pancreatic cancer in patients<sup>123</sup>. Similarly, a nanoparticle-based chip was engineered for high-throughput identification of cEVs in small quantities in plasma samples<sup>124</sup> (Fig. 3A). Using this platform, EPHA2 was identified as a potential biomarker of early-stages pancreatic cancer and response to treatment in patients<sup>124</sup>. Alternative approaches for isolation of cEVs in patients, such as double-filtration microfluidics, sequential filtration, or surface plasmon resonance, which have been used for detection of tumor lesions in glioblastoma, prostate, ovarian, and breast cancer, might also be repurposed for detection of early-stage pancreatic cancer<sup>125, 126</sup>. In addition, because of the role of cEVs in facilitating establish the pre-metastatic niche<sup>39</sup>, cEVs could be monitored to detect tumor metastasis.

Given the extent of the stromal alteration during solid tumor progression, circulating stroma-derived markers have also been tested as potential diagnostic biomarkers. For example, circulating collagens fragments and thrombospondin-2 have been identified in serum and plasma of cancer patients<sup>127, 128</sup>, and persistence of collagen in the blood following surgery have been suggested to predict disease relapse or poor outcomes of patients with pancreatic cancer,<sup>129</sup> as well as metastatic disease in patients with colorectal cancer<sup>130</sup>. Similarly, circulating markers of collagen turnover such as MMPs and tissue inhibitor of metalloproteinases have been found in the serum of cancer patients and might be used to



detect fibrotic changes occurring during pancreatic cancer progression<sup>131,132</sup>. Circulating CAFs (cCAFs) have also been detected in mouse models of breast and lung cancer as well as in blood from cancer patients, and this correlated with metastatic disease<sup>133,134</sup> (Fig. 3A). This could be used to detect pancreatic tumors or to monitor tumor response to treatment. Similarly, immune cells that recognize tumor antigens, such as monocytes and neoantigen-specific lymphocytes, were found in blood of patients with melanoma or colorectal cancer<sup>135,136</sup> (Fig. 3A). Given the immune reaction occurring during pancreatic cancer, circulating immune cells that recognize tumor antigens might represent additional markers to identify patients with early-stage pancreatic cancer<sup>72</sup>.

In patients, imaging technologies such as computed tomography, endoscopic ultrasound or positron emission tomography (PET), have been used to detect pancreatic tumors and to monitor cancer progression and response to treatments (Fig. 3B). Given the stromal alterations occurring during pancreatic cancer development, imaging technologies can be developed that might allow clinicians to detect changes in the pancreatic stroma in a non-invasive manner, while also providing information about the tumor response to stroma manipulation.

Technologies have been developed to image changes in pulmonary and liver fibrosis in patients, and might be used to detect fibrotic alterations in patients with pancreatic cancer. A PET-based probe was recently developed for the detection of young and fibrotic collagen in patients with idiopathic pulmonary fibrosis<sup>137</sup>. The probe allowed for sensitive detection of fibrotic tissue in the lungs, staging of disease development, and monitoring the efficacy of anti-fibrosis agents in mice and patients<sup>137</sup> (Fig. 3B). Similarly, cathepsin protease probes and PET probes to detect  $\alpha_5\beta_1$ -integrin were engineered for non-invasive imaging of fibrotic tissue in lungs and liver<sup>138,139</sup>. In addition, features of the gut microbiome were also shown to serve as markers of fibrotic changes in the liver<sup>140</sup>. Together, tools assessing gastro-intestinal cancers could be repurposed for detection of fibrosis in early-stage pancreatic tumors and other types of cancer, at primary and metastatic sites. Measurements of tissue stiffness could also be achieved by revisiting techniques such as elastography, previously used to detect fibrotic tissues following liver transplantation<sup>141</sup>, or using magnetically responsive ferrofluid microdroplets, which have recently been used to assess mechanical events that promote organ development<sup>142</sup> (Fig. 3B).

Tumors might also be stratified based on their fibrotic signature for instance using automated second harmonic generation imaging (SHG)<sup>33</sup>, which provides label-free imaging of non-centrosymmetric entities such as crosslinked collagen fibers, or using immunohistochemical staining of HA content in patient biopsies (clinical trial HaLo 109-202 and HaLo 301<sup>143</sup>, Table 1). These approaches might guide the development of personalized anti-stroma manipulation for patients with pancreatic cancer. Importantly, although the molecular profiles of pancreatic tumors are highly heterogeneous<sup>61,144,148</sup>, these studies suggest that stratifying patients based on a tumor's stromal signature, rather than solely that of the cancer cells, might provide the most useful information for the development of precision stromal medicine in combination with chemotherapy.

The metabolic switch that occurs in cancer cells during tumor development has been used as the standard for detection of a tumor mass in an organism. Our increasing understanding of tumor metabolism has led to the development of tools for detection of precursor pancreatic cancer lesions<sup>99</sup>. For instance, 18-FDG PET imaging relies upon imaging tumor's avidity for glucose, whereas glutamine-based PET probes have been developed for detection of tumors in animals and have been tested in patients with glioblastoma<sup>149, 150</sup>. Similarly, pancreatic cancer progression has been shown to be accompanied by a decrease in the ratio of alanine:lactate in primary tumors of mice, and this can be imaged using <sup>13</sup>C magnetic resonance<sup>151</sup> (Fig. 3B). This approach could be used for early, non-invasive, radiation-free detection of pancreatic cancer. Finally, subtle changes in the tumor vasculature were recently detected in mice with ovarian or breast tumors using non-invasive techniques such as ultrasound imaging<sup>152-154</sup>, Doppler ultrasonography,<sup>155</sup> and optical coherence tomography<sup>156</sup>; these approaches could also be used for patients with pancreatic cancer (Fig. 3B).

The recent development of sensitive, cost-effective, and faster diagnostic tools could facilitate early detection of tumor lesions. This would allow for earlier therapeutic intervention and/or surgery to be offered to a larger number of patients.

### **Modeling the stroma and patient's response to stromal manipulation**

Testing the efficacy of anti-stroma agents can be facilitated using in vitro and in vivo tools that mimic some stromal compartments of human tumors. These tools allow researchers to optimize manipulation of the stroma before clinical assessments. Each of these models is

specifically designed to study specific events occurring during cancer progression (see Figs. 4 and 5). More detailed information on the current and future applications as well as caveats of these models can be found in Fig. 4 and Fig. 5. For instance, tumors that develop in genetically engineered mice and PDXs recapitulate many of the stromal and genomic features found in the tumor environment<sup>157-161</sup>, and are powerful tools for development of strategies for precision cancer medicine<sup>33, 56, 162-167</sup> (Fig. 4A). Organoids are also emerging as miniature platform for studying tumor development<sup>168-170</sup>—stem cells, cultured under specific conditions, spontaneously generate structures that contain much of the architecture, functions, and genetic features of the tissue of origin<sup>171-174</sup>. Organoids display some features of the tissue stroma, and might be used to study the effects of anti-stromal agents in combination with chemotherapy<sup>84, 175</sup>. In addition, the generation of organoids derived from patient tissues may facilitate the development of individualized therapies in pancreatic cancer<sup>84, 176-178</sup> (Fig. 4B).

Three-dimensional organotypic matrices, designed based on specific features of individual pancreatic tumors, have been developed to optimize selection of anti-stroma agents<sup>33, 56, 179</sup>. In this system, patients' cancer cells and fibroblasts that have been exposed to the cancer cells are used to mimic tumor–ECM interactions in a collagen matrix<sup>43, 56</sup>. This approach can be used for faster testing of stromal manipulation before assessment in vivo (Fig. 4C). This is relevant to pancreatic cancer pre-clinical research because of the need and interest for precision medicines, due to pancreatic tumor heterogeneity<sup>61, 144-147</sup>.

More insights into the properties and functions of the ECM were also provided by decellularization protocols, which allow the complete removal of cells from tissues, leaving the native ECM intact<sup>180-183</sup>. This technique was recently used to catalogue matrix alterations that occur during breast cancer development in multiple sites and has been used to catalogue ECM and angiogenic changes in pancreatic tumors<sup>67, 180</sup> (Fig. 5A). Lastly, bioengineered scaffolds with adjustable properties enable researchers to generate 3-dimensional tailored matrices with controlled mechanical and biochemical features. These tools have been used to investigate how the ECM promotes angiogenesis, cancer cell intravasation, drug diffusion, migration of endothelial cells<sup>184, 185</sup>, EMT<sup>10</sup> and the metabolic activity of pancreatic cancer cells<sup>186, 187</sup> (Fig. 5B). Together, these approaches could provide important insights into tumor–stroma interactions occurring during tumor progression and could guide the development of stroma-targeting agents for patient-specific treatment of pancreatic cancer.

566

567 **Future Directions**

568 Agents and fine-tuned strategies designed to target the specific stromal features of pancreatic  
569 tumors offer new opportunities for the development of stromal-based therapies in this  
570 disease. Fine-tuned manipulation of the tumor stroma, using carefully timed, sequential  
571 targeting of multiple stromal compartments can deprive cancer cells of the supportive stromal  
572 niche in primary tumors and metastases, without disrupting most normal tissue functions.  
573 The stromal fingerprint of pancreatic cancer, like its epithelial counterpart, is heterogeneous,  
574 and as such the development of stromal-based biomarkers may facilitate identification of  
575 patients that could benefit from subtle manipulation of the stroma prior to, and in addition to  
576 standard-of-care therapy. Pancreatic cancer treatment is in an exciting phase, where fine-  
577 tuned, sequential treatment regimens as well as targeting of specific stromal compartments  
578 are set to improve patients' outcome in this devastating disease.

579

**Figure 1. Manipulating the tumor stroma reduces progression and metastasis**

A) Pre-clinical assessment of stromal manipulation in the context of primary tumors and metastatic disease.

B) Limitations and benefits of long-term exposure to stromal agents (i), pulsed and iterative administration of anti-stromal agents (ii) and sequential targeting of multiple stromal compartments (iii).

**Figure 2. Stromal targets in pancreatic tumors**

A) Agents and targets for manipulation of the ECM. Left: SHG imaging of the ECM in subcutaneous xenografts; right hand image: polarized image of picosirius red staining in subcutaneous xenografts. Adapted from<sup>93</sup>.

B) Strategies for normalization of the tumor vasculature. Red: blood vessel (quantum dot); blue: collagen (SHG signal).

C) Approaches to induce quiescence in CAFs. Fluorescent image of a spheroid containing A341-EcadKO cancer cells (magenta) and CAFs (blue). Scale bar: 100  $\mu$ m. Adapted from<sup>95</sup>.

D) Immune-based therapies for pancreatic cancer. Infiltration of CD45<sup>+</sup> immune cells (red) in pancreatic tumor tissues, containing cancer cells (blue) and CAFs (green). Adapted from<sup>134</sup>.

E) Approaches for blocking the metabolic switch associated with pancreatic cancer progression. Images show the mass-spectrometry signal used to detect aspartate and glutamate (left) and overlaid onto a bright-field image of the tissue section (right). Adapted from<sup>106</sup>.

**Figure 3. Tools for early detection of pancreatic cancer**

A) Liquid biopsies can be used to identify patients with pancreatic cancer. (i) Circulating extracellular vesicles can be detected using high-throughput plasmon sensor chip (left, adapted from<sup>123</sup>) or nanoplasmonic technologies (right, adapted from<sup>124</sup>, scale bar=2  $\mu$ m). (ii) Detection of circulating CAFs (green) clustered with CTCs (red) (adapted from<sup>132</sup>). (iii) Isolation of circulating, immune cells (lymphocytes) from patients' tumors and matched peripheral blood mononuclear cells (PBMCs) by flow cytometry (adapted from<sup>135</sup>).

B) Imaging and detection of stromal alterations occurring during pancreatic cancer progression in patients (i) Detection of fibrotic tissue using PET-based probes. Image represents detection of fibrotic tissue in the liver using PET-based probe, adapted from<sup>137</sup>. (ii) Visualization of liver fibrosis and of changes in the mechanical properties of tissue using acoustic radiation force impulse elastography (adapted from<sup>141</sup>). (iii) Detection of aberrant metabolic activity by monitoring alanine:lactate ratio using <sup>13</sup>C magnetic resonance imaging in mice with pancreatic tumors and metastases (adapted from<sup>151</sup>). (iv) Mapping of subtle changes of the tumor vasculature using acoustic angiography (adapted from<sup>154</sup>, left panel: acoustic angiography image of the tumor and surrounding tissue; right: vessel segmentation following acoustic angiography) and via micro-ultrasound and photoacoustic imaging. Image represents heat map of wash-in of gas-filled micromarker in pancreatic tumor tissue. Blue: low-wash-in; red, high wash-in. Adapted from<sup>153</sup>.

#### **Figure 4. Three-dimensional in vitro and in vivo models of tumor–stroma interactions for development of personalized treatment**

Description, applications, limitations and future directions of (A) patient-derived xenografts; (B) organoids (image adapted from<sup>178</sup> and representing pancreatic organoids cultured for 2 weeks in human complete media. hN1: organoid derived from human normal pancreas, hT1: organoid derived from human pancreatic tumor) and (C) personalized organotypic matrices (adapted from<sup>93</sup>).

#### **Figure 5. Three-dimensional tools for studying tumor–stroma interactions and testing anti-stroma agents**

Description, applications, limitations and future directions of (A) decellularization protocols (image adapted from<sup>180</sup>, top: image of polymer casting in the vascular compartment of pulmonary ECM, lower: fibril-orientation analysis overlay of SHG in decellularized tissue) and (B) 3-dimensional bioengineered scaffolds (image adapted from<sup>187</sup> and representing scaffold engineered using melt electrospun).

Table 1: Clinical trials in pancreatic cancer assessing stroma manipulation.

643  
644  
645  
646  
647  
648  
649  
650

**Acknowledgments**

The authors wish to thank Dr. Sean Warren for critical reading of the manuscript.

**Conflict of interest statement**

No competing or financial interests declared.

## References

1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014;74:2913-21.
2. Sinha S, Leach SD. New insights in the development of pancreatic cancer. *Curr Opin Gastroenterol* 2016.
3. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. *Nat Rev Dis Primers* 2016;2:16022.
4. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep* 2014;15:1243-53.
5. Cox T, Erler J. Fibrosis and cancer: partner in crime or opposing forces? *Trends in Cancer* 2016;2 279 - 282.
6. Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and extracellular matrix homeostasis. *Nat Rev Mol Cell Biol* 2014;15:802-12.
7. Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. *Nat Med* 2016;22:497-505.
8. Kalluri R. The biology and function of fibroblasts in cancer. *Nat Rev Cancer* 2016;16:582-98.
9. Wormann SM, Song L, Ai J, et al. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. *Gastroenterology* 2016;151:180-193 e12.
10. Rice AJ, Cortes E, Lachowski D, et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. *Oncogenesis* 2017;6:e352.
11. Horejs CM, St-Pierre JP, Ojala JRM, et al. Preventing tissue fibrosis by local biomaterials interfacing of specific cryptic extracellular matrix information. *Nat Commun* 2017;8:15509.
12. Krebs AM, Mitschke J, Laserra Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. *Nat Cell Biol* 2017;19:518-529.
13. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 2009;324:1457-61.
14. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012;21:418-29.
15. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut* 2013;62:112-20.
16. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003;4:437-50.
17. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* 2005;7:469-83.



- 699 18. Catenacci DV, Junttila MR, Karrison T, et al. Randomized Phase Ib/II Study  
700 of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway  
701 Inhibitor, in Patients With Metastatic Pancreatic Cancer. *J Clin Oncol*  
702 2015;33:4284-92.
- 703 19. Ko AH, LoConte N, Tempero MA, et al. A Phase I Study of FOLFIRINOX Plus  
704 IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic  
705 Adenocarcinoma. *Pancreas* 2016;45:370-5.
- 706 20. Hingorani SR, Harris W, Hendifar A, et al. High response rate and PFS with  
707 PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously  
708 untreated pancreatic cancer patients with high-HA tumors: interim results  
709 of a randomized phase 2 study. *ASCO Annual Meeting* 2015;30:4134.
- 710 21. Wong KM, Horton KJ, Coveler AL, et al. Targeting the Tumor Stroma: the  
711 Biology and Clinical Development of Pegylated Recombinant Human  
712 Hyaluronidase (PEGPH20). *Curr Oncol Rep* 2017;19:47.
- 713 22. Miller BW, Morton JP, Pinese M, et al. Targeting the LOX/hypoxia axis  
714 reverses many of the features that make pancreatic cancer deadly:  
715 inhibition of LOX abrogates metastasis and enhances drug efficacy. *EMBO*  
716 *Mol Med* 2015;7:1063-76.
- 717 23. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain,  
718 rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell*  
719 2014;25:735-47.
- 720 24. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-  
721 associated fibroblasts and fibrosis induces immunosuppression and  
722 accelerates pancreas cancer with reduced survival. *Cancer Cell*  
723 2014;25:719-34.
- 724 25. Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug  
725 delivery and potentiates chemotherapy by decompressing tumour blood  
726 vessels. *Nat Commun* 2013;4:2516.
- 727 26. Steeg PS. Targeting metastasis. *Nat Rev Cancer* 2016;16:201-18.
- 728 27. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the  
729 genetic evolution of pancreatic cancer. *Nature* 2010;467:1114-7.
- 730 28. Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic  
731 cancer evolution based on genomic rearrangement patterns. *Nature*  
732 2016;538:378-382.
- 733 29. Chin VT, Nagrial AM, Chou A, et al. Rho-associated kinase signalling and the  
734 cancer microenvironment: novel biological implications and therapeutic  
735 opportunities. *Expert Rev Mol Med* 2015;17:e17.
- 736 30. Whatcott CJ, Ng S, Bearrett M, et al. Inhibition of ROCK1 kinase modulates  
737 both tumor cells and stromal fibroblasts in pancreatic cancer. *Plos One*  
738 2017;12:e0183871.
- 739 31. Holvoet T, Devriese S, Castermans K, et al. Treatment of Intestinal Fibrosis  
740 in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of  
741 a Local Rho Kinase Inhibitor. *Gastroenterology* 2017;153:1054-1067.
- 742 32. Rath N, Morton JP, Julian L, et al. ROCK signaling promotes collagen  
743 remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor  
744 cell growth. *EMBO Mol Med* 2017;9:198-218.
- 745 33. Vennin C, Chin VT, Warren SC, et al. Transient tissue priming via ROCK  
746 inhibition uncouples pancreatic cancer progression, sensitivity to  
747 chemotherapy, and metastasis. *Sci Transl Med* 2017;9.

- 748 34. Yeatman TJ. A renaissance for SRC. *Nat Rev Cancer* 2004;4:470-80.
- 749 35. Erami Z, Herrmann D, Warren SC, et al. Intravital FRAP Imaging using an E-  
750 cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic  
751 Regulation of Cell-Cell Junctions in Live Tissue. *Cell Rep* 2016;14:152-67.
- 752 36. Evans T, Van Cutsem E, Moore M, et al. Dasatinib combined with  
753 gemcitabine (Gem) in patients (pts) with locally advanced pancreatic  
754 adenocarcinoma (PaCa): CA180-375, double-blind phase II trial. *J Clin*  
755 *Oncol* 2012.
- 756 37. Morton JP, Karim SA, Graham K, et al. Dasatinib inhibits the development  
757 of metastases in a mouse model of pancreatic ductal adenocarcinoma.  
758 *Gastroenterology* 2010;139:292-303.
- 759 38. Hirata E, Girotti MR, Viros A, et al. Intravital imaging reveals how BRAF  
760 inhibition generates drug-tolerant microenvironments with high integrin  
761 beta1/FAK signaling. *Cancer Cell* 2015;27:574-88.
- 762 39. Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific  
763 homes for metastases. *Nat Rev Cancer* 2017;17:302-317.
- 764 40. Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes  
765 initiate pre-metastatic niche formation in the liver. *Nat Cell Biol*  
766 2015;17:816-26.
- 767 41. Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins  
768 determine organotropic metastasis. *Nature* 2015;527:329-35.
- 769 42. Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, et al. Blocking Surgically  
770 Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. *Cell*  
771 *Rep* 2017;19:774-784.
- 772 43. Barkan D, El Touny LH, Michalowski AM, et al. Metastatic growth from  
773 dormant cells induced by a col-I-enriched fibrotic environment. *Cancer Res*  
774 2010;70:5706-16.
- 775 44. Li X, Kang Y, Roife D, et al. Prolonged exposure to extracellular lumican  
776 restrains pancreatic adenocarcinoma growth. *Oncogene* 2017;36:5432-  
777 5438.
- 778 45. Baar MP, Brandt RM, Putavet DA, et al. Targeted Apoptosis of Senescent  
779 Cells Restores Tissue Homeostasis in Response to Chemotoxicity and  
780 Aging. *Cell* 2017;169:132-147 e16.
- 781 46. Rajbhandari N, Lin WC, Wehde BL, et al. Autocrine IGF1 Signaling Mediates  
782 Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers. *Cell*  
783 *Rep* 2017;18:2243-2255.
- 784 47. Lin W, Rajbhandari N, Wagner K. Cancer cell dormancy in novel mouse  
785 models for reversible pancreatic cancer: a lingering challenge in the  
786 development of targeted therapies. *Cancer Research*  
787 2014;74:2138-2143.
- 788 48. Steele C, Karim SA, Leach JDG, et al. CXCR2 Inhibition Profoundly  
789 Suppresses Metastases and Augments Immunotherapy in Pancreatic  
790 Ductal Adenocarcinoma. *Cancer Cell* 2016;29:832-845.
- 791 49. Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome  
792 induces pre-metastatic bone lesions through lysyl oxidase. *Nature*  
793 2015;522:106-10.
- 794 50. Chiou SH, Risca VI, Wang GX, et al. BLIMP1 Induces Transient Metastatic  
795 Heterogeneity in Pancreatic Cancer. *Cancer Discov* 2017;7:1184-1199.

51. Aiello NM, Bajor DL, Norgard RJ, et al. Metastatic progression is associated with dynamic changes in the local microenvironment. *Nat Commun* 2016;7:12819.
52. Harris NL, Vennin C, Conway JR, et al. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. *Oncogene* 2017;36:4288-4298.
53. Nobis M, Herrmann D, Warren S, et al. A RhoA-FRET biosensor mouse for intravital imaging in normal tissue homeostasis and disease contexts. *Cell Reports* 2017;21:274-288.
54. Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. *Nat Med* 2016;22:851-60.
55. Chakraborty S, Njah K, Pobbati A, et al. Agrin as a Mechanotransduction Signal Regulating YAP through the Hippo Pathway. *Cell Reports* 2017;02:2464-2479.
56. Chou A, Froio D, Nagrial A, et al. Tailored First- and Second-Line CDK4-Targeting Treatment Combinations in Mice with Pancreatic Cancer. *Gut* 2017;In press.
57. Yeo D, Phillips P, Baldwin GS, et al. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. *Int J Cancer* 2017;140:2101-2111.
58. Pajic M, Herrmann D, Vennin C, et al. The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. *Small GTPases* 2015;6:123-33.
59. Ridley AJ. Rho proteins and cancer. *Breast Cancer Res Treat* 2004;84:13-9.
60. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. *EMBO Rep* 2012;13:900-8.
61. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531:47-52.
62. Samuel MS, Lopez JL, McGhee EJ, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. *Cancer Cell* 2011;19:776-91.
63. Lane J, Martin TA, Watkins G, et al. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. *International Journal of Oncology* 2008;33:585-593.
64. Miroshnikova YA, Mouw JK, Barnes JM, et al. Tissue mechanics promote IDH1-dependent HIF1alpha-tenascin C feedback to regulate glioblastoma aggression. *Nat Cell Biol* 2016;18:1336-1345.
65. Bordeleau F, Mason BN, Lollis EM, et al. Matrix stiffening promotes a tumor vasculature phenotype. *Proc Natl Acad Sci U S A* 2017;114:492-497.
66. Reid SE, Kay EJ, Neilson LJ, et al. Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. *EMBO J* 2017;36:2373-2389.
67. Naba A, Clauser KR, Mani DR, et al. Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. *Sci Rep* 2017;7:40495.

68. Rahbari NN, Kedrin D, Incio J, et al. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. *Sci Transl Med* 2016;8:360ra135.
69. Rohrig F, Vorlova S, Hoffmann H, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. *Oncogene* 2017;36:1-12.
70. Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. *Nat Med* 2016;22:1294-1302.
71. Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. *Cancer Cell* 2017;31:311-325.
72. Balachandran V, Łuksza M, Zhao J, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. *Nature* 2017;000.
73. Kunk PR, Bauer TW, Slingluff CL, et al. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. *J Immunother Cancer* 2016;4:14.
74. Ene-Obong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. *Gastroenterology* 2013;145:1121-32.
75. Froeling FE, Feig C, Chelala C, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. *Gastroenterology* 2011;141:1486-97.
76. Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A* 2013;110:20212-7.
77. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. *Science* 2010;330:827-30.
78. Sharon Y, Raz Y, Cohen N, et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. *Cancer Res* 2015;75:963-73.
79. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. *Cell* 2014;159:80-93.
80. Afik R, Zigmond E, Vugman M, et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix. *J Exp Med* 2016;213:2315-2331.
81. Carstens JL, Correa de Sampaio P, Yang D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. *Nat Commun* 2017;8:15095.
82. Hanley CJ, Noble F, Ward M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. *Oncotarget* 2016;7:6159-74.
83. Torres S, Bartolome RA, Mendes M, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. *Clin Cancer Res* 2013;19:6006-19.

84. Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med* 2017;214:579-596.
85. Labernadie A, Kato T, Brugues A, et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. *Nat Cell Biol* 2017;19:224-237.
86. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med* 2008;14:518-27.
87. Kim DE, Procopio MG, Ghosh S, et al. Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. *J Exp Med* 2017;214:2349-2368.
88. Le CP, Nowell CJ, Kim-Fuchs C, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. *Nat Commun* 2016;7:10634.
89. Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. *Nature* 2017;544:250-254.
90. Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. *Sci Transl Med* 2017;9.
91. Peterson TE, Kirkpatrick ND, Huang Y, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. *Proc Natl Acad Sci U S A* 2016;113:4470-5.
92. Jamieson T, Clarke M, Steele CW, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. *J Clin Invest* 2012;122:3127-44.
93. Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci Transl Med* 2014;6:237ra67.
94. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. *Cancer Cell* 2015;27:462-72.
95. Arlauckas SP, Garriss CS, Kohler RH, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. *Sci Transl Med* 2017;9.
96. Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. *Clin Cancer Res* 2017;in press.
97. Chin V, Vennin C, Timpson P, et al. Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing? *Molecular and Cellular Oncology* 2017;e1333973
98. Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map. *J Immunother Cancer* 2017;5:16.
99. Halbrook CJ, Lyssiotis CA. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. *Cancer Cell* 2017;31:5-19.
100. Sherman MH, Yu RT, Tseng TW, et al. Stromal cues regulate the pancreatic cancer epigenome and metabolome. *Proc Natl Acad Sci U S A* 2017;114:1129-1134.

- 940 101. Sousa CM, Biancur DE, Wang X, et al. Pancreatic stellate cells support  
941 tumour metabolism through autophagic alanine secretion. *Nature*  
942 2016;536:479-83.
- 943 102. Zhao H, Yang L, Baddour J, et al. Tumor microenvironment derived  
944 exosomes pleiotropically modulate cancer cell metabolism. *Elife*  
945 2016;5:e10250.
- 946 103. Georgiadou M, Lilja J, Jacquemet G, et al. AMPK negatively regulates tensin-  
947 dependent integrin activity. *J Cell Biol* 2017;216:1107-1121.
- 948 104. Dornier E, Norman JC. Tensin links energy metabolism to extracellular  
949 matrix assembly. *J Cell Biol* 2017;216:867-869.
- 950 105. Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis  
951 of protein is an amino acid supply route in Ras-transformed cells. *Nature*  
952 2013;497:633-7.
- 953 106. Davidson SM, Jonas O, Keibler MA, et al. Direct evidence for cancer-cell-  
954 autonomous extracellular protein catabolism in pancreatic tumors. *Nat*  
955 *Med* 2017;23:235-241.
- 956 107. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic  
957 evidence and biologic mechanisms. *Mol Carcinog* 2012;51:53-63.
- 958 108. Incio J, Liu H, Suboj P, et al. Obesity-Induced Inflammation and  
959 Desmoplasia Promote Pancreatic Cancer Progression and Resistance to  
960 Chemotherapy. *Cancer Discov* 2016;6:852-69.
- 961 109. Incio J, Suboj P, Chin SM, et al. Metformin Reduces Desmoplasia in  
962 Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated  
963 Macrophages. *PLoS One* 2015;10:e0141392.
- 964 110. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A  
965 induces oxidative stress and inhibits tumor progression. *Proc Natl Acad Sci*  
966 *U S A* 2010;107:2037-42.
- 967 111. Daemen A, Peterson D, Sahu N, et al. Metabolite profiling stratifies  
968 pancreatic ductal adenocarcinomas into subtypes with distinct  
969 sensitivities to metabolic inhibitors. *Proc Natl Acad Sci U S A*  
970 2015;112:E4410-7.
- 971 112. Maddocks ODK, Athineos D, Cheung EC, et al. Modulating the therapeutic  
972 response of tumours to dietary serine and glycine starvation. *Nature*  
973 2017;544:372-376.
- 974 113. Koplev S, Longden J, Ferkinghoff-Borg J, et al. Dynamic Rearrangement of  
975 Cell States Detected by Systematic Screening of Sequential Anticancer  
976 Treatments. *Cell Reports* 2017;20:2784-91.
- 977 114. D'Costa Z, Jones K, Azad A, et al. Gemcitabine-induced TIMP1 attenuates  
978 therapy response and promotes tumor growth and liver metastasis in  
979 pancreatic cancer. *Cancer Res* 2017;in press.
- 980 115. Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of  
981 nab-paclitaxel in pancreatic cancer. *Br J Cancer* 2013;109:926-33.
- 982 116. Neesse A, Algul H, Tuveson DA, et al. Stromal biology and therapy in  
983 pancreatic cancer: a changing paradigm. *Gut* 2015;64:1476-84.
- 984 117. Moravec R, Divi R, Verma M. Detecting circulating tumor material and  
985 digital pathology imaging during pancreatic cancer progression. *World J*  
986 *Gastrointest Oncol* 2017;9:235-250.

987 118. Capello M, Bantis LE, Scelo G, et al. Sequential Validation of Blood-Based  
988 Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. *J Natl*  
989 *Cancer Inst* 2017;109.

990 119. Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS  
991 in circulating exosome-derived DNA from early-stage pancreatic cancer  
992 patients. *Ann Oncol* 2017;28:741-747.

993 120. Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein  
994 and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis  
995 increases sensitivity and specificity. *Int J Cancer* 2015;136:2616-27.

996 121. Chen D, Wu X, Xia M, et al. Upregulated exosomal miR23b3p plays  
997 regulatory roles in the progression of pancreatic cancer. *Oncol Rep*  
998 2017;38:2182-2188.

999 122. Bavisotto C, Cappello F, Macario AJL, et al. Exosomal HSP60: a potentially  
1000 useful biomarker for diagnosis, assessing prognosis, and monitoring  
1001 response to treatment. *Expert Rev Mol Diagn* 2017;17:815-822.

1002 123. Yang KS, Im H, Hong S, et al. Multiparametric plasma EV profiling facilitates  
1003 diagnosis of pancreatic malignancy. *Sci Transl Med* 2017;9.

1004 124. Liang K, Liu F, Fan J, et al. Nanoplasmonic Quantification of Tumor-derived  
1005 Extracellular Vesicles in Plasma Microsamples for Diagnosis and  
1006 Treatment Monitoring. *Nat Biomed Eng* 2017;1.

1007 125. Heinemann ML, Vykoukal J. Sequential Filtration: A Gentle Method for the  
1008 Isolation of Functional Extracellular Vesicles. *Methods Mol Biol*  
1009 2017;1660:33-41.

1010 126. Liang LG, Sheng YF, Zhou S, et al. An Integrated Double-Filtration  
1011 Microfluidic Device for Detection of Extracellular Vesicles from Urine for  
1012 Bladder Cancer Diagnosis. *Methods Mol Biol* 2017;1660:355-364.

1013 127. Willumsen N, Bager C, Diana J, et al. Extracellular matrix specific protein  
1014 fingerprints measured in serum can separate pancreatic cancer patients  
1015 from healthy controls. *BMC Cancer* 2013;2013:554.

1016 128. Kim J, Bamlet WR, Oberg AL, et al. Detection of early pancreatic ductal  
1017 adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. *Sci*  
1018 *Transl Med* 2017;9.

1019 129. Ohlund D, Lundin. C, Ardnor. B, et al. Type IV collagen is a tumour stroma-  
1020 derived biomarker for pancreas cancer. *Br J Cancer* 2009;1:91-7.

1021 130. Kehlet SN, Sanz-Pamplona R, Brix S, et al. Excessive collagen turnover  
1022 products are released during colorectal cancer progression and elevated in  
1023 serum from metastatic colorectal cancer patients. *Sci Rep* 2016;6:30599.

1024 131. Joergensen M, Brunner N, De Muckadell O. Comparison of circulating MMP-  
1025 9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. *Anticancer Res*  
1026 2010;30:587-92.

1027 132. Jackson HW, Defamie V, Waterhouse P, et al. TIMPs: versatile extracellular  
1028 regulators in cancer. *Nat Rev Cancer* 2017;17:38-53.

1029 133. Ao Z, Shah SH, Machlin LM, et al. Identification of Cancer-Associated  
1030 Fibroblasts in Circulating Blood from Patients with Metastatic Breast  
1031 Cancer. *Cancer Res* 2015;75:4681-7.

1032 134. Duda D, Duyverman A, Kohno M SM, Steller EJ, Fukumura D, Jain RK.  
1033 Malignant cells facilitate lung metastasis by bringing their own soil. *Proc*  
1034 *Natl Acad Sci U S A* 2010:21677-21682. .

1035 135. Gros A, Parkhurst MR, Tran E, et al. Prospective identification of  
1036 neoantigen-specific lymphocytes in the peripheral blood of melanoma  
1037 patients. *Nat Med* 2016;22:433-8.

1038 136. Hamm A, Prenen H, Van Delm W, et al. Tumour-educated circulating  
1039 monocytes are powerful candidate biomarkers for diagnosis and disease  
1040 follow-up of colorectal cancer. *Gut* 2016;65:990-1000.

1041 137. Desogere P, Tapias LF, Hariri LP, et al. Type I collagen-targeted PET probe  
1042 for pulmonary fibrosis detection and staging in preclinical models. *Sci*  
1043 *Transl Med* 2017;9.

1044 138. Dakanali M, Lo S, Hassan G, et al. Detection of liver fibrosis based on an  $\alpha$  v  
1045  $\beta$  6-integrin targeted PET probe. *The Journal of Nuclear Medicine*  
1046 2014;55:12-41.

1047 139. Withana NP, Ma X, McGuire HM, et al. Non-invasive Imaging of Idiopathic  
1048 Pulmonary Fibrosis Using Cathepsin Protease Probes. *Sci Rep*  
1049 2016;6:19755.

1050 140. Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic  
1051 Signature for Non-invasive Detection of Advanced Fibrosis in Human  
1052 Nonalcoholic Fatty Liver Disease. *Cell Metab* 2017;25:1054-1062 e5.

1053 141. Haberal K, Turnaoğlu H, Özdemir A, et al. Measurements Using Acoustic  
1054 Radiation Force Impulse in Recipients of Living-Donor and Deceased-  
1055 Donor Orthotopic Liver Transplant. *Exp Clin Transplant* 2017;in press.

1056 142. Serwane F, Mongera A, Rowghanian P, et al. In vivo quantification of  
1057 spatially varying mechanical properties in developing tissues. *Nat Methods*  
1058 2017;14:181-186.

1059 143. Hingorani S.R. WPH, Andrew Eugene Hendifar, Andrea J. Bullock, Xionghua  
1060 W. Wu, Ya Huang, Ping Jiang. High response rate and PFS with PEGPH20  
1061 added to nab-paclitaxel/gemcitabine in stage IV previously untreated  
1062 pancreatic cancer patients with high-HA tumors: interim results of a  
1063 randomized phase 2 study. *ASCO Annual Meeting* 2015.

1064 144. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal  
1065 adenocarcinoma and their differing responses to therapy. *Nat Med*  
1066 2011;17:500-3.

1067 145. Network. CGAR. Integrated Genomic Characterization of Pancreatic Ductal  
1068 Adenocarcinoma. *Cancer Cell* 2017;32:185-203 e13.

1069 146. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes  
1070 reveal aberrations in axon guidance pathway genes. *Nature* 2012;491:399-  
1071 405.

1072 147. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the  
1073 mutational landscape of pancreatic cancer. *Nature* 2015;518:495-501.

1074 148. Lowery MA, Jordan EJ, Basturk O, et al. Real-Time Genomic Profiling of  
1075 Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation  
1076 with Clinical Phenotype. *Clin Cancer Res* 2017.

1077 149. Venneti S, Dunphy MP, Zhang H, et al. Glutamine-based PET imaging  
1078 facilitates enhanced metabolic evaluation of gliomas in vivo. *Sci Transl*  
1079 *Med* 2015;7:274ra17.

1080 150. Lieberman BP, Ploessl K, Wang L, et al. PET imaging of glutaminolysis in  
1081 tumors by 18F-(2S,4R)4-fluoroglutamine. *J Nucl Med* 2011;52:1947-55.



- 1082 151. Serrao EM, Kettunen MI, Rodrigues TB, et al. MRI with hyperpolarised [1-  
1083 <sup>13</sup>C]pyruvate detects advanced pancreatic preneoplasia prior to invasive  
1084 disease in a mouse model. *Gut* 2016;65:465-75.
- 1085 152. Rao SR, Shelton SE, Dayton PA. The "Fingerprint" of Cancer Extends  
1086 Beyond Solid Tumor Boundaries: Assessment With a Novel Ultrasound  
1087 Imaging Approach. *IEEE Trans Biomed Eng* 2016;63:1082-6.
- 1088 153. Lakshman M, Needle A. Screening and quantification of the tumor  
1089 microenvironment with micro-ultrasound and photoacoustic imaging.  
1090 *Nature Methods* 2015;12.
- 1091 154. Rao KS, Chaudhary AK. Comparative Study of Ultraviolet Laser-Based  
1092 Time-Resolved Photoacoustic Fingerprint Spectra and Thermal  
1093 Decomposition Mechanisms of Energetic 1,2,3-1H-Triazole Derivatives  
1094 Under Controlled Pyrolysis. *Appl Spectrosc* 2017;71:1481-1493.
- 1095 155. Barua A, Bitterman P, Bahr JM, et al. Detection of tumor-associated  
1096 neoangiogenesis by Doppler ultrasonography during early-stage ovarian  
1097 cancer in laying hens: a preclinical model of human spontaneous ovarian  
1098 cancer. *J Ultrasound Med* 2010;29:173-82.
- 1099 156. Liang CP, Nakajima T, Watanabe R, et al. Real-time monitoring of  
1100 hemodynamic changes in tumor vessels during photoimmunotherapy  
1101 using optical coherence tomography. *J Biomed Opt* 2014;19:98004.
- 1102 157. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical  
1103 testing of novel cancer therapeutics. *Clin Cancer Res* 2006;12:5277-87.
- 1104 158. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models:  
1105 an emerging platform for translational cancer research. *Cancer Discov*  
1106 2014;4:998-1013.
- 1107 159. Bruna A, Rueda OM, Greenwood W, et al. A Biobank of Breast Cancer  
1108 Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer  
1109 Compounds. *Cell* 2016;167:260-274 e22.
- 1110 160. DeRose YS, Wang G, Lin YC, et al. Tumor grafts derived from women with  
1111 breast cancer authentically reflect tumor pathology, growth, metastasis  
1112 and disease outcomes. *Nat Med* 2011;17:1514-20.
- 1113 161. Eirew P, Steif A, Khattra J, et al. Dynamics of genomic clones in breast  
1114 cancer patient xenografts at single-cell resolution. *Nature* 2015;518:422-6.
- 1115 162. Herrera-Abreu MT, Palafox M, Asghar U, et al. Early Adaptation and  
1116 Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive  
1117 Breast Cancer. *Cancer Res* 2016;76:2301-13.
- 1118 163. Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-  
1119 derived tumor xenografts to predict clinical trial drug response. *Nat Med*  
1120 2015;21:1318-25.
- 1121 164. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for  
1122 translational drug development in pancreatic cancer. *Clin Cancer Res*  
1123 2006;12:4652-61.
- 1124 165. Witkiewicz AK, Balaji U, Eslinger C, et al. Integrated Patient-Derived  
1125 Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic  
1126 Cancer. *Cell Rep* 2016;16:2017-31.
- 1127 166. Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a  
1128 stem-cell program in human metastatic breast cancer cells. *Nature*  
1129 2015;526:131-5.

1130 167. Kemper K, Krijgsman O, Cornelissen-Steijger P, et al. Intra- and inter-tumor  
1131 heterogeneity in a vemurafenib-resistant melanoma patient and derived  
1132 xenografts. *EMBO Mol Med* 2015;7:1104-18.

1133 168. Cortina C, Turon G, Stork D, et al. A genome editing approach to study  
1134 cancer stem cells in human tumors. *EMBO Mol Med* 2017;9:869-879.

1135 169. Riemer P, Rydenfelt M, Marks M, et al. Oncogenic beta-catenin and PIK3CA  
1136 instruct network states and cancer phenotypes in intestinal organoids. *J*  
1137 *Cell Biol* 2017;216:1567-1577.

1138 170. Dai X, Gan W, Li X, et al. Prostate cancer-associated SPOP mutations confer  
1139 resistance to BET inhibitors through stabilization of BRD4. *Nat Med* 2017.

1140 171. Clevers H. Modeling Development and Disease with Organoids. *Cell*  
1141 2016;165:1586-1597.

1142 172. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling  
1143 development and disease using organoid technologies. *Science*  
1144 2014;345:1247125.

1145 173. Bredenoord AL, Clevers H, Knoblich JA. Human tissues in a dish: The  
1146 research and ethical implications of organoid technology. *Science*  
1147 2017;355.

1148 174. Cammareri P, Vincent DF, Hodder MC, et al. TGFbeta pathway limits  
1149 dedifferentiation following WNT and MAPK pathway activation to  
1150 suppress intestinal tumourigenesis. *Cell Death Differ* 2017;24:1681-1693.

1151 175. Dekkers JF, Berkens G, Kruisselbrink E, et al. Characterizing responses to  
1152 CFTR-modulating drugs using rectal organoids derived from subjects with  
1153 cystic fibrosis. *Sci Transl Med* 2016;8:344ra84.

1154 176. Bartucci M, Ferrari AC, Kim IY, et al. Personalized Medicine Approaches in  
1155 Prostate Cancer Employing Patient Derived 3D Organoids and Humanized  
1156 Mice. *Front Cell Dev Biol* 2016;4:64.

1157 177. Dotti I, Mora-Buch R, Ferrer-Picon E, et al. Alterations in the epithelial stem  
1158 cell compartment could contribute to permanent changes in the mucosa of  
1159 patients with ulcerative colitis. *Gut* 2016;0:1-11.

1160 178. Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse  
1161 ductal pancreatic cancer. *Cell* 2015;160:324-38.

1162 179. Coleman SJ, Watt J, Arumugam P, et al. Pancreatic cancer organotypics:  
1163 High throughput, preclinical models for pharmacological agent evaluation.  
1164 *World J Gastroenterol* 2014;20:8471-81.

1165 180. Mayorca-Guiliani AE, Madsen CD, Cox TR, et al. ISDoT: in situ  
1166 decellularization of tissues for high-resolution imaging and proteomic  
1167 analysis of native extracellular matrix. *Nature Medicine* 2017;23:890-898.

1168 181. Ke MT, Fujimoto S, Imai T. SeeDB: a simple and morphology-preserving  
1169 optical clearing agent for neuronal circuit reconstruction. *Nat Neurosci*  
1170 2013;16:1154-61.

1171 182. Pinto ML, Rios E, Silva AC, et al. Decellularized human colorectal cancer  
1172 matrices polarize macrophages towards an anti-inflammatory phenotype  
1173 promoting cancer cell invasion via CCL18. *Biomaterials* 2017;124:211-224.

1174 183. Wan J, Huang Y, Zhou P, et al. Culture of iPSCs Derived Pancreatic beta-Like  
1175 Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary  
1176 Trial. *Biomed Res Int* 2017;2017:4276928.

- 1177 184. Magno V, Friedrichs J, Weber HM, et al. Macromolecular crowding for  
1178 tailoring tissue-derived fibrillated matrices. *Acta Biomater* 2017;55:109-  
1179 119.
- 1180 185. Morgan JP, Delnero PF, Zheng Y, et al. Formation of microvascular  
1181 networks in vitro. *Nat Protoc* 2013;8:1820-36.
- 1182 186. Holzapfel NP, Holzapfel BM, Theodoropoulos C, et al. Lycopene's Effects on  
1183 Cancer Cell Functions within Monolayer and Spheroid Cultures. *Nutr*  
1184 *Cancer* 2016;68:350-63.
- 1185 187. Muerza-Cascante ML, Shokoohmand A, Khosrotehrani K, et al. Endosteal-  
1186 like extracellular matrix expression on melt electrospun written scaffolds.  
1187 *Acta Biomater* 2017;52:145-158.  
1188